GlassScriptPhysician profile
Ashkan Lashkari
NPI 1528284627
$39,829.05
in general payments reported to CMS, 2019-2025
70 companies · $5,174 in 2025
The $5,174 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,880 · 2021: $1,794 · 2022: $7,182 · 2023: $3,574 · 2024: $6,781 · 2025: $5,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,985 · Food and Beverage: $4,948 · Long Term Medical Supply Or Device Loan: $1,446 · Education: $132 · Travel and Lodging: $17.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,985.00 |
| Food and Beverage | $4,948.03 |
| Long Term Medical Supply Or Device Loan | $1,446.39 |
| Education | $132.49 |
| Travel and Lodging | $17.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $9,637.82 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Eli Lilly and Company | $4,375.00 | 2022 | |
| Genzyme Corporation | $4,224.90 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $3,956.85 | 2019-2025 | Talvey |
| Lilly USA, LLC | $2,962.64 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $2,612.36 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $2,473.17 | 2020-2023 | Xpovio |
| Beigene USA, INC. | $1,950.00 | 2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $948.77 | 2019-2025 | Enhertu, Calquence, Lynparza |
| Celgene Corporation | $791.20 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $688.96 | 2019-2025 | |
| Janssen Biotech, INC. | $497.95 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Seagen INC. | $396.98 | 2019-2023 | Adcetris, Tukysa |
| Astellas Pharma US INC | $262.68 | 2023-2025 | Xospata, Vyloy, Padcev |
| Pharmaessentia USA Corporation | $243.72 | 2024-2025 | Besremi |
Show all 69 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashkan Lashkari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.